NATIXIS PARTNERS ADVISED PAI PARTNERS AND THE MANAGEMENT TEAM IN THE SALE OF ELITECHGROUP TO BRUKER CORPORATION

ELITechGroup, a manufacturer of equipment and reagents for in vitro diagnostics, was acquired by the publicly traded American group Bruker Corporation. The 'Clinical Chemistry' division is excluded from the scope of the transaction. Founded in 1997, the Group, which generates nearly €150 million in revenue (excluding the Clinical Chemistry division), develops, manufactures, and sells its analysis instruments, reagents, and software to hospitals and diagnostic laboratories in over 100 countries. It specializes in molecular diagnostics systems, biomedical systems, and microbiology. The Group experienced strong growth in recent years under the leadership of its management and PAI Partners, the majority shareholder since 2017, through both external and organic growth with the internal development of new molecular analysis machines. ELITechGroup employs over 600 employees, mainly distributed across its sites in Europe (France, Italy, Germany) and the United States. Bruker Corporation is a US multinational company manufacturing analysis instruments for various applications (pharmaceutical, scientific research, environmental, industrial, etc.) and generates nearly $3.0 billion in revenue. The acquisition of ELITechGroup will complement its portfolio of diagnostic products for infectious diseases. Natixis Partners acted as advisor to the Group and its shareholders in this transaction.